Jennifer Halchak; VP, IR; Organon & Co. Kevin Ali; Chief Executive Officer, Director; Organon & Co. Matthew Walsh; Chief Financial Officer, Senior Vice President; Or ...

For recently acquired Tofidence, that product is manufactured in China, but we have inventory coverage offering us protection through 2025. The denosumab asset from Shanghai Henlius is not planned ...

The intravenous biosimilar of IL-6 inhibitor Actemra (tocilizumab) – called Tofidence (formerly BIIB800) – has been cleared for three of the indications for which Roche’s drug is used ...